Can anticoagulation be withdrawn in APS patients after aPL negativization?

Area of Science:

• Hematology
• Immunology
• Rheumatology

Background:

• Long-term anticoagulation with vitamin K antagonists (VKAs) is standard for thrombotic antiphospholipid syndrome (APS).
• The possibility of discontinuing anticoagulation in APS patients who achieve antiphospholipid antibody (aPL) negativization is under discussion.
• aPL negativization is often defined as two negative tests, one year apart, though consensus is lacking.

Purpose of the Study:

• To review the available evidence on the phenomenon of aPL negativization in APS patients.
• To discuss the implications of aPL negativization for the management of anticoagulation in APS.
• To highlight key features to consider when deciding whether to stop anticoagulation in APS patients with negative aPL tests.

Main Methods:

• Literature review of studies investigating aPL negativization in patients with thrombotic APS.
• Analysis of factors associated with aPL negativization and recurrent thrombosis.
• Synthesis of expert opinions and guidelines regarding anticoagulation management post-aPL negativization.

Main Results:

• The frequency and predictors of aPL negativization in APS are variable.
• Evidence regarding the safety and efficacy of stopping anticoagulation after aPL negativization is limited and conflicting.
• Risk stratification for recurrent thrombosis in aPL-negative APS patients remains a challenge.

Conclusions:

• aPL negativization occurs in a subset of APS patients, but its clinical significance for anticoagulation management requires further investigation.
• Decisions on stopping anticoagulation should be individualized, considering patient-specific risk factors and the evolving understanding of aPL dynamics.
• Further research is needed to establish clear guidelines for optimizing anticoagulation strategies in APS patients experiencing aPL negativization.